Dilraj Singh Grewal

Dilraj Singh Grewal

Auto-generated profile, based on publicly available information

Dilraj Singh Grewal

Department of Ophthalmology, Duke University School of Medicine, Durham, NC, USA

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2016 in JAMA Ophthalmology
Verified
Journal Article
Closed access
PDF file
DGDilraj S. Grewal
Dilraj S. Grewal
TMTamer H. Mahmoud
Tamer H. Mahmoud
Review from JAMA Ophthalmology — Autologous Neurosensory Retinal Free Flap for Closure of Refractory Myopic Macular Holes

1 June 2019 in Ophthalmology Retina
Verified
Journal Article
Closed access
SYStephen P. Yoon
Stephen P. Yoon
DGDilraj S. Grewal
Dilraj S. Grewal
ATAtalie C. Thompson
Atalie C. Thompson
BPBryce W. Polascik
Bryce W. Polascik
CDCynthia Dunn
Cynthia Dunn
SFSharon Fekrat
Sharon Fekrat

1 February 2021 in JAMA Ophthalmology
Verified
Journal Article
Open access
PDF file
CRCason B. Robbins
Cason B. Robbins
ATAtalie C. Thompson
Atalie C. Thompson
PBParamjit K. Bhullar
Paramjit K. Bhullar
HKHui Yan Koo
Hui Yan Koo
RARupesh Agrawal
Rupesh Agrawal
SFSharon Fekrat
Sharon Fekrat
Parkinson disease (PD) is a progressive neurodegenerative condition that involves prominent motor dysfunction and nonmotor symptoms consistent with the loss of dopaminergic neurons in the substantia nigra that is attributed to the pathological accumulation of α-synuclein within cells.1-3 The global impact of PD is increasing as the population ages, with its prevalence more than doubling from 1990 (2.5 million cases) to 2016 (6.1 million cases).4

1 March 2009 in Journal of Cataract & Refractive Surgery
Verified
Journal Article
Closed access
DGDilraj S. Grewal
Dilraj S. Grewal
GBGagandeep S. Brar
Gagandeep S. Brar
RJRajeev Jain
Rajeev Jain
VSVardaan Sood
Vardaan Sood
MSMohit Singla
Mohit Singla
SGSatinder Pal Singh Grewal
Satinder Pal Singh Grewal
To evaluate changes in corneal curvature, corneal elevation, corneal thickness, lens density, and foveal thickness after corneal collagen crosslinking with riboflavin and ultraviolet-A (UVA) light in eyes with progressive keratoconus. Grewal Eye Institute, Chandigarh, India. Subjective refraction, best corrected visual acuity (BCVA), Scheimpflug imaging, and optical coherence tomography were performed preoperatively and 1 week, 1, 3, and 6 months, and 1 year after crosslinking. There were no significant differences (P > 0.05) in mean values between preoperatively and 1 year postoperatively, respectively, in BCVA (0.22 +/- 0.10 and 0.20 +/- 0.10), spherical equivalent (-6.30 +/- 4.50 diopters (D) and -4.90 +/- 3.50 D), or cylinder vector (1.58 x 7( degrees ) +/- 3.8 D and 1.41 x 24( degrees ) +/- 3.5 D). There was no significant difference in mean measurements between preoperatively and 1 year postoperatively, respectively, for central corneal thickness (458.9 +/- 40 microm and 455.2 +/- 48.6 microm), anterior corneal curvature (50.6 +/- 7.4 D and 51.5 +/- 3.6 D), posterior corneal curvature (-7.7 +/- 1.2 D and -7.4 +/- 1.1 D), apex anterior (P = .9), posterior corneal elevation (P = .7), lens density (P = .33), or foveal thickness (175.7 +/- 35.6 microm and 146.4 +/- 8.5 microm; P = .1). Stable BCVA, spherical equivalent, anterior and posterior corneal curvatures, and corneal elevation 1 year after crosslinking indicate that keratoconus did not progress. Unchanged lens density and foveal thickness suggest that the lens and macula were not affected after UVA exposure during crosslinking.

1 October 2019 in Ophthalmology
Verified
Journal Article
Closed access
DGDilraj S. Grewal
Dilraj S. Grewal
SCSteve Charles
Steve Charles
Barbara ParoliniBarbara Parolini
Barbara Parolini
KKKazuaki Kadonosono
Kazuaki Kadonosono
TMTamer H. Mahmoud
Tamer H. Mahmoud

1 May 2014 in Retina
Verified
Journal Article
Closed access
DGDilraj S. Grewal
Dilraj S. Grewal
GFGerald A. Fishman
Gerald A. Fishman
LJLee M. Jampol
Lee M. Jampol
To review the current state for diagnosis and management of autoimmune retinopathy. A review of the literature was performed, encompassing autoimmune retinopathy including paraneoplastic retinopathy (cancer-associated retinopathy, melanoma-associated retinopathy, and bilateral diffuse uveal melanocytic proliferation) and non-paraneoplastic autoimmune retinopathy. Based on this review, current principles and techniques for diagnosis and the treatments reported for autoimmune retinopathy are discussed with the aim to clarify some of the confusion that exists regarding this complex entity. Autoimmune retinopathy encompasses a spectrum of retinal degeneration phenotypes. The clinical features, fundus characteristics, and electroretinogram findings for paraneoplastic and non-paraneoplastic retinopathy are reviewed. The different antiretinal antibodies reported in these entities are described. The diagnostic approaches for detecting these antiretinal antibodies and their limitations are covered. The treatments reported for autoimmune retinopathy and their outcomes are reviewed. Among the myriad of antiretinal antibodies reported, challenges persist in determining which antibodies are pathogenic and which are benign and what factors cause antiretinal antibodies to become pathologic. There also remain difficulties in the detection and accurate measurement of antiretinal antibodies, and the response to therapeutic intervention in autoimmune retinopathy is variable.